The RESOLVE trial is a Phase 1b/2a, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically ...

The study recommends a 50 mg daily dose for global treatment development, based on integrated pharmacokinetics, safety, and efficacy data. Investors are advised to exercise caution as the drug’s ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

General & Administrative Expenses - G&A expenses were $1.1 million in the third quarter of 2024, compared to $1.2 million for the third quarter of 2023, a slight decrease of $0.1 million. G&A expenses ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Pharmaceutical spectroscopy techniques like NMR, mass spectrometry, and UV-Vis play essential roles in pharmacokinetics, supporting each stage of drug development from discovery and preclinical ...

Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Greetings and welcome to the Fulgent Genetics Q3 2024 Conference ...

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. <li /> Consistent improve ...

With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Breakthrough polymer-based therapy shows promise in reversing Huntington's disease symptoms by preventing toxic protein ...